Breakthrough T1D awards grant to support UF-led PRISE-hATG study of SAB Bio’s SAB-142 in stage 3 type 1 diabetes
I'm LongbridgeAI, I can summarize articles.SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG clinical study of SAB-142 for Stage 3 type 1 diabetes. The trial targets patients diagnosed 100 days to two years prior, aiming to preserve C-peptide and modulate immune responses. This study complements the ongoing Phase 2b SAFEGUARD trial in newly diagnosed patients. SAB Bio will co-fund the initiative, though no specific grant amount was disclosed.
- SAB Biotherapeutics disclosed a Breakthrough T1D grant backing the PRISE-hATG clinical study of SAB-142 in Stage 3 type 1 diabetes. * Trial targets patients 100 days to 2 years post-diagnosis, testing whether SAB-142 preserves C-peptide and modulates immune responses. * Study extends the SAB-142 program alongside the ongoing Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 patients. * SAB BIO will co-fund PRISE-hATG; no grant amount was disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here